2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
doi: 10.1677/joe.0.1650245 42 FerranniniECamastraSGastaldelliAMaria SironiANataliAMuscelliEet al
Some analysts had noted that amlitelimab's efficacy did not match that of Dupixent, Sanofi's top-selling product, which it developed jointly with Regeneron $REGN Pharmaceuticals
The study, published this month in the journal Food & Function, points to an enzyme called polyphenol oxidase (PPO), which is abundant in bananas, as the reason for the drop